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Abstract
Background
Between 19%-44% pregnant women are prescribed antibiotics during pregnancy. A single,
large randomised-controlled-trial (ORACLE Childhood Study II) found an increased risk of
childhood cerebral palsy and possibly epilepsy following prophylactic antibiotic use in preg-
nant women with spontaneous preterm labour. We ascertained whether this outcome could
be reproduced across the population of babies delivered at term and prospectively followed
in primary-care using data from The Health Improvement Network.
Methods
We determined the risk of cerebral palsy or epilepsy in children whose mothers were pre-
scribed antibiotics during pregnancy using a cohort of 195,909 women linked to their live,
term-born, singleton children. We compared the effect of antibiotic class, number of courses
and timing of prescribing in pregnancy. Analyses were adjusted for maternal risk factors (e.
g. recorded infection, age, chronic conditions, social deprivation, smoking status). Children
were followed until age seven years or cessation of registration with the primary-
care practitioner.
Results
In total, 64,623 (33.0%) women were prescribed antibiotics in pregnancy and 1,170 (0.60%)
children had records indicating cerebral palsy or epilepsy. Adjusted analyses showed no as-
sociation between prescribing of any antibiotic and cerebral palsy or epilepsy (adj.HR 1.04,
95%CI 0.91–1.19). However, compared with penicillins, macrolides were associated with
an increased risk of cerebral palsy or epilepsy (adj.HR 1.78, 95%CI 1.18–2.69; number
needed to harm 153, 95%CI 71–671).
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We found no overall association between antibiotic prescribing in pregnancy and cerebral
palsy and/or epilepsy in childhood. However, our finding of an increased risk of cerebral
palsy or epilepsy associated with macrolide prescribing in pregnancy adds to evidence that
macrolide use is associated with serious harm.
INTRODUCTION
Antibiotics are one of the most frequently prescribed medications in pregnancy, with estimates
of antibiotic use in pregnancy ranging from 19% to 44%.[1–6] When deciding whether to
taken any form of pharmacologic treatment during pregnancy, women (and the healthcare
professionals treating them) need to be sure that overall benefits outweigh potential harm to
the fetus.[7,8] There is strong evidence for net benefits of prenatal antibiotics for mother and
child when infection is the predominant underlying mechanism of effect. For example, prenatal
antibiotics are effective for women with suspected bacterial infections (e.g urinary tract infec-
tions [UTI][9]) and as prophylaxis for women with asymptomatic bacteriuria[10] and preterm
prolonged rupture of membranes.[11]
Unexpected evidence of harm associated with prenatal antibiotics was provided by a single
large (N>4,000) randomised-controlled-trial (RCT) of prophylactic antibiotics for women in
spontaneous preterm labour.[12] This trial, the Oracle Childhood Study (OCS) II, evaluated
children at the age of seven years whose mothers had been randomised to receive erythromy-
cin, co-amoxiclav, both, or placebo during pregnancy. Most children were born at term and
were delivered greater than seven days after trial entry.[12] Women who received both erythro-
mycin and co-amoxiclav had an increased risk of having a child with cerebral palsy (odds ratio
[OR]: 2.93; 95% confidence interval [CI]: 1.50–5.65) or epilepsy (OR: 1.53; 95%CI: 1.07–2.20)
compared to women randomised to receive placebo.[12–14] These findings may be explained
by harm due to antibiotics, possibly from prolonged exposure to inflammatory processes in the
intrauterine environment due to partially treated infection.[15] Alternatively, the apparent ad-
verse effect of antibiotics may be explained by biases due to ‘damaged-survivors’ in analyses
that were conditioned on survivors of infancy—where stillbirths, infant deaths and children
lost-to-follow up were excluded.[16]
Antibiotics are now not recommended for women in preterm labour without overt evidence
of infection and further RCTs to confirm or refute the findings of OCS II are unlikely.[17]
Large, longitudinal primary-care databases are widely used to investigate drug safety and are
particularly useful for exploring unexpected adverse effects.[18] We therefore analysed prima-
ry-care data to determine whether antibiotic prescribing (for any indication) during pregnancy
was associated with cerebral palsy or epilepsy in children and whether risk of cerebral palsy or
epilepsy varied according to the timing, number of courses, and class of antibiotic prescribed.
We hypothesised that there would be no association between prenatal antibiotic prescribing
and cerebral palsy and/or epilepsy in childhood.
METHODS
Data Source
We used The Health Improvement Network (THIN) which captures prospective, anonymised
data on prescriptions, diagnoses, and symptoms in primary-care for approximately 6% of the
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and criteria.United Kingdom population.[19] Prescription data are automatically recorded when prescrip-
tions are issued, and they are classified according to the British National Formulary (BNF).
[20,21] Significant medical events are recorded by clinicians and coded using the Read system.
[22] Data on contact with secondary-care and socio-demographic status are also available.
THIN is broadly representative of the UK population and captures valid and complete data.
[23–27]
Study design
We analysed a retrospective cohort of women who were linked to their live-born children
using deterministic (exact) linkage methods. The following variables were considered when
linking mothers and children: family ID number, mother’s actual or estimated date of delivery,
child’s month and/or year of birth, and gestational age at delivery/birth.
Participants
Inception to the cohort was restricted to women aged 15–50 years between January 1990 and
May 2010, who had registered at their primary-care practice before pregnancy and who had a
singleton, child born at or after term (37 weeks of gestation or more). Where gestational age at
delivery was uncertain and evidence of pre- or post-term birth was lacking (37%), we assumed
pregnancy lasted 40 weeks. For women with multiple pregnancies (approximately 24% in the
cohort), we randomly selected one pregnancy for analysis. Children born preterm were exclud-
ed because their increased risk of cerebral palsy and epilepsy (related to prenatal, perinatal and
postnatal risk factors) could mask any association with antibiotic prescribing in pregnancy. For
consistency with the OCS II study[12], follow-up ended at the earliest of seven completed years
of age, the date the child left their primary-care practice, death, or the end of the study (May
2010).
Antibiotic prescriptions
We considered women as treated if they had a prescription record between the last menstrual
period and estimated delivery date for any antibiotic in chapter 5.1 of the British National For-
mulary (BNF), excluding those with topical formulations such as antibiotics used to treat acne
(BNF chapter 13.6.1) and conjunctivitis (BNF chapter 11.3.1). A list of the generic antibiotics
considered is provided in S1 Appendix—Codes used to identify women with antibiotic pre-
scriptions in pregnancy. All other women were considered as untreated. Antibiotics pre-
scribed and dispensed by hospitals are not captured in THIN, but are likely to affect very few
women in this study. Except for women whose illness or labour requires hospital care, treat-
ment would normally be prescribed by the primary-care practitioner. Intrapartum antibiotic
prescribing has been estimated to involve less than 5% of women, including those delivering
preterm.[28]
Cerebral palsy or epilepsy
The pre-specified primary outcome was cerebral palsy and/or epilepsy recorded in a child’s pri-
mary-care record up to seven years old. We grouped cerebral palsy and epilepsy for the follow-
ing reasons: 1. they often co-occur; 2. they have common prenatal aetiologies; 3. they were
associated with prenatal antibiotic prescribing in the OCS II study; and 4. to increase statistical
power for our analyses of timing, number of courses and type of antibiotic prescribed.
We used a previously published and validated algorithm to identify children with epilepsy
which was based on one or more codes for an epilepsy diagnosis, symptoms (multiple seizure
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details, and code lists, are provided in S2 Appendix—Description of algorithm and codes
used to identify children with epilepsy. A similar algorithm was developed to identify children
with cerebral palsy, whereby codes for diagnoses, symptoms (e.g. spasticity), treatment (e.g. in-
tramuscular injection of baclofen) and management procedures (e.g. tenotomy) were used to
identify children with possible cerebral palsy. We then reviewed the full medical records of all
children with possible cerebral palsy and excluded (from consideration as a child with cerebral
palsy) those without consistent evidence of a non-progressive motor disorder. All reviewers
were blinded as to whether a child’s mother was prescribed antibiotics during pregnancy. Addi-
tional details are available in S3 Appendix—Description of algorithm and codes used to
identify children with cerebral palsy.
The outcome date was the earliest date upon which evidence for cerebral palsy or epilepsy
was recorded.
Maternal risk factors for both antibiotic prescribing in pregnancy and
cerebral palsy and/or epilepsy in the child
We classified the following maternal risk factors: maternal age at delivery, pregnancy complica-
tions (e.g. any record indicating hypertension or diabetes), chronic conditions (e.g. obesity
prior to pregnancy [BMI30 or Read code for obesity], treatment for chronic medical condi-
tions during pregnancy)[30], behaviours (e.g. recent smoking/tobacco use, alcohol or illicit
drug misuse at any time), social deprivation (measured by the Townsend score quintile where
Q1 is most affluent and Q5 is most deprived [31]), maternal infection that was a potentially
neurologically-damaging infection (PNDI) for the fetus (e.g. UTIs and chorioamnionitis; see
S4 Appendix—Read codes used to identify women with potentially neurologically-damag-
ing infections in pregnancy).[32,33] These maternal risk factors were chosen a priori based on
evidence from the literature of associations between these factors and both our exposure and
outcomes of interest. We assumed that absence of codes for maternal conditions indicated ab-
sence of those conditions.
Analysis
We used a series of Cox regression models to compare the time to cerebral palsy and/or epilep-
sy in different groups of women who were and were not prescribed antibiotics in pregnancy. In
the primary analysis we compared children whose mothers received one or more antibiotic
prescriptions with those whose mothers had no recorded antibiotic prescription. Adjustment
was made for potential maternal confounders using the propensity score for antibiotic pre-
scribing. This was derived using all maternal risk factors (for antibiotic prescribing and for hav-
ing a child with cerebral palsy and/or epilepsy) listed previously as well as calendar year of
delivery.[34] Ten women with non-overlapping propensity score distributions were trimmed
from the analysis cohort. We further adjusted this and all other analyses for potential clustering
at the level of primary-care practice by using robust standard errors. Assumptions of propor-
tional hazards were met for this and all other models.
In a sensitivity analysis (designed to minimise bias due to the type of infection for which an-
tibiotics were prescribed—not to minimise bias due to infection severity) we repeated the
above analysis using a restricted cohort which included women with a single respiratory tract
infection recorded in pregnancy and compared children whose mothers received an antibiotic
prescription for a respiratory tract infection with children whose mothers were not prescribed
antibiotics for their respiratory tract infection. Women with respiratory tract infections in
Prenatal Antibiotics, Cerebral Palsy and Epilepsy
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codes used to identify women with respiratory tract infections in pregnancy.
In secondary analyses we determined the effect of number, timing and type of antibiotic
prescriptions in pregnancy on the time to cerebral palsy and/or epilepsy. To assess the effect of
number of courses of antibiotics prescribed (where each separate prescription was defined as a
single course), we categorised the variable for antibiotic treatment into a four-level variable
(none, one, two or three or more courses). We determined the association with the class (type)
and timing of antibiotic prescription in analyses restricted to women prescribed a single course
of antibiotics. Class of antibiotic was grouped according to BNF sub-chapters (e.g. penicillins,
aminoglycosides, macrolides, tetracyclines). Pencillins were chosen as the referent group be-
cause they were the most commonly prescribed class of antibiotics in pregnancy and have the
longest history of safe use in pregnancy. To assess timing, we categorised prescriptions within
four week periods (lunar month) of gestational age. Here, the first lunar month was arbitrarily
chosen as the referent group. In all secondary analyses, we accounted for potential confounding
using a stepwise approach to model building, as propensity scores are only valid with binary ex-
posure variables. Numbers needed to harm were estimated at age seven years using methods of
Altman et al.[35]
Finally, in post-hoc analyses requested by a reviewer, we repeated the primary analysis (any
versus no antibiotic) and one secondary analysis (class of antibiotic versus penicillins) on risk
of epilepsy.
All authors designed the study. WM performed the analyses, with input and advice from
RG. Code lists were reviewed by GPs, a paediatrician (RG), and an epileptologist.
Ethics Statement
Research using data from THIN has blanket ethics approval from the South East Multi-Centre
Research Ethics Committee. All data in THIN are anonymised and researchers do not have ac-
cess to any identifiable information such as names, NHS numbers, postcodes or full birthdays.
This study received additional approval from the THIN scientific review committee (13_008).
RESULTS
We identified a cohort of 195,909 women linked to their singleton children born at or after
term. The cohort comprised all mother-child pairs in THIN meeting the study eligibility crite-
ria. The children were followed up from birth for a median of 3.6 years (inter quartile range
[IQR] 1.5–7.2). Median follow-up differed by outcome status—children with cerebral palsy
and/or epilepsy were followed-up for 6.5 years (IQR 3.5–10.3) whilst children without were fol-
lowed-up for 3.7 years (IQR 1.6–7.2). In total, 1,170 (0.6%) children had evidence of cerebral
palsy (n = 232), epilepsy (n = 874) or both (n = 64) in their medical records, and 64,623 (33%)
were prescribed antibiotics during pregnancy.
Compared to women not prescribed antibiotics, women prescribed antibiotics (Table 1)
were on average more deprived, more likely to be obese (15.5% vs 10.9%), to receive treatment
for chronic medical conditions in pregnancy (14.9% vs 9.2%), to have problems with alcohol
(1.7% vs 1.1%) to use tobacco (28.6% vs 21.5%) or illicit drugs (1.6% vs 0.9%), and to have an
infection which could potentially cause fetal neuro-damage (23.2% vs 4.2%).
Unadjusted analyses showed an increased risk of cerebral palsy and/or epilepsy in children
born to women prescribed antibiotics compared with women with no recorded prescriptions
(Table 2: unadj. hazard ratio [HR] 1.20; 95%CI 1.06–1.35; p = 0.004). However, after adjusting
for potential confounders, no significant association was evident (adj.HR 1.04; 95% CI 0.91–
1.19; p = 0.5). In sensitivity analyses restricted to women with a single respiratory tract
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ic prescribing and cerebral palsy or epilepsy (Table 2). The post-hoc analysis for epilepsy also
showed no significant association between any antibiotic prescribing during pregnancy and the
risk of epilepsy in childhood, after adjusting for potential confounders (adj.HR 1.03; 95%CI
0.89–1.10; p = 0.7).
Whilst we found no association with the timing of antibiotic prescription and cerebral palsy
or epilepsy, we found that children whose mothers received 3+ prescriptions during pregnancy
had a 40% increased risk (adj.HR 1.40; 95%CI 1.07–1.83; p = 0.01) compared to those with no
prescriptions (Table 3). The incidence of cerebral palsy or epilepsy in children whose mothers
received 3+ prescriptions in pregnancy was 261.1 (95%CI 210.5–323.7) per 100,000 child-
years-at-risk (CYAR) compared to 143.8 (95%CI 133.8–154.5) in children whose mothers re-
ceived no prescriptions. The number needed to harm was 291 (95%CI 141–191) at age
seven years.
Table 1. Characteristics of women in the cohort.
Variable Number (%) without
an antibiotic
prescription recorded
(n = 131,286)
Number (%) with an
antibiotic
prescription
recorded
(n = 64,623)
All 131,286 (67.0%) 64,623 (33.0%)
Obese prior to pregnancy 14,371 (10.9%) 10,011 (15.5%)
Illicit drug use 1,190 (0.9%) 1,020 (1.6%)
Current smoking / tobacco use 28,209 (21.5%) 18,457 (28.6%)
Alcohol problems 1,488 (1.1%) 1,101 (1.7%)
Treatment for chronic medical condition in pregnancy 12,023 (9.2%) 9,633 (14.9%)
Social deprivation Townsend quintile based on postcode of residence) 1 (most afﬂuent) 34,699 (26.4%) 14,250 (22.1%)
2 27,322 (20.8%) 12,031 (18.6%)
3 27,303 (20.8%) 13,407 (20.7%)
4 24,683 (18.8%) 13,744 (21.3%)
5 most deprived) 17,279 (13.2%) 11,191 (17.3%)
Age at delivery 15–19 6,196 (4.7%) 4,429 (6.9%)
20–24 18,318 (14.0%) 11,668 (18.1%)
25–29 34,756 (26.5%) 17,367 (26.9%)
30–34 42,868 (32.7%) 18,791 (29.1%)
35–39 24,054 (18.3%) 10,227 (15.8%)
40–50 5,094 (3.9%) 2,141 (3.3%)
Calendar year of delivery 1990–94 7,383 (5.6%) 3,629 (5.6%)
1995–99 17,501 (13.3%) 9,051 (14.0%)
2000–04 41,848 (31.9%) 19,031 (29.4%)
2005–10 64,554 (49.2%) 32,912 (50.9%)
Diabetes in pregnancy 2,944 (2.2%) 1,902 (2.9%)
Hypertension in pregnancy 4,380 (3.3%) 2,499 (3.9%)
Potentially neurologically-damaging infection in pregnancy 5,538 (4.2%) 14,978 (23.2%)
NB. Absence of information on obesity, illicit drug use, smoking, alcohol problems, treatment for chronic medical conditions, diabetes and hypertension
in a mothers’ medical record was interpreted as absence of the condition.
doi:10.1371/journal.pone.0122034.t001
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95%CI 1.18–2.69; p = 0.006) compared to those prescribed penicillins (Table 3). The incidence
of cerebral palsy or epilepsy in children whose mothers were prescribed macrolides was 254.6
per 100,000 CYAR (95%CI 175.6–368.3) compared to 143.6 (95%CI 122.8–169.0) in children
whose mothers were prescribed penicillin. The number need to harm was 153 (95%CI 71–671)
at age seven years. The post-hoc analysis which looked at epilepsy as the outcome, found that
macrolide versus penicillin prescribing in pregnancy was associated with a doubling in the risk
of epilepsy in childhood (adj.HR 2.02; 95%CI 1.30–3.14; p = 0.002).
DISCUSSION
We found no evidence for an increased risk of cerebral palsy and/or epilepsy in children of
women prescribed any antibiotics in pregnancy compared with no antibiotics after taking into
account maternal risk factors for treatment. Children of women prescribed three courses or
more of antibiotics compared with none did have an increased risk of cerebral palsy or epilepsy
which may reflect the risks associated with recurrent infections. We also found an increased
risk of cerebral palsy or epilepsy in children of women prescribed macrolides compared
with penicillins.
Strengths of our study are the large cohort, the fact that THIN captures all primary-care pre-
scribing (though not dispensing), and the longitudinal records allowing follow up into child-
hood. One weakness, inherent in observational studies, is confounding of the relationship
between antibiotic prescribing and childhood cerebral palsy or epilepsy by maternal risk factors
(such as parity which is not reliably recorded in UK primary care), and particularly by maternal
infections that indicated antibiotic treatment.
We adjusted analyses for maternal risk factors including maternal infections for which there
was evidence of an association with fetal neuro-damage (PNDI). We considered maternal in-
fection to be a confounder in the analyses as there is evidence from numerous studies that cer-
tain maternal infections cause fetal neurological damage[32,33] and mothers with infections
are more likely to receive antibiotics. Failure to adjust for maternal infections can produce spu-
rious associations that reflect the infection not the treatment. For example, two Danish popula-
tion-based studies used antibiotic prescribing in pregnancy as a proxy for maternal infection.
Table 2. Women prescribed antibiotics versus never prescribed: time to cerebral palsy and/or epilepsy in childhood.
Number mother-child
pairs in analysis
Number (%)
prescribed
antibiotics
Number children with any
cerebral palsy or epilepsy
Unadjusted
hazard ratio
(95%
conﬁdence
interval)
Adjusted†
hazard ratio
(95%
conﬁdence
interval)
All women 195,899 64,613 (33.0%) 1,170 1.20* (1.06,
1.35)
1.04 (0.91,
1.19)
Women with a single
respiratory tract infection‡
17,822 7,266 (40.8%) 83 0.99 (0.65,
1.51)
0.94 (0.62,
1.42)
*p<0.01
† Cox regression model adjusted for propensity score which included: hypertension, smoking/tobacco use, diabetes, age at delivery, year of delivery,
Townsend quintile, treatment of chronic medical condition in pregnancy, alcohol problems, illicit drug use, obesity and potentially neurologically-
damaging infection during pregnancy.
‡ Analysis cohort included women with a single respiratory tract infection who either received or did not receive a single antibiotic prescription within plus
or minus three days of the recorded date of respiratory tract infection.
doi:10.1371/journal.pone.0122034.t002
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PLOS ONE | DOI:10.1371/journal.pone.0122034 March 25, 2015 8/1 4They reported associations between prenatal antibiotic prescribing and adverse neurological
outcome in childhood, which are likely to reflect adverse effects of infections in pregnancy.
[36,37] We also endeavoured to minimise the potential adverse effects of antibiotics due to
their beneficial effects on infection by conducting a pre-planned sensitivity analysis restricted
to women with ‘treated’ and ‘untreated’ respiratory tract infections. Because respiratory tract
infections diagnosed in primary-care are usually of viral aetiology[38], any benefits due to anti-
biotic treatment of bacterial respiratory tract infection would be small or negligible, thereby in-
creasing the chance of detecting potential adverse effects of antibiotic treatment. However, we
were unable to measure infection severity—more severe infections would be linked to adverse
fetal effects but would be more likely to be treated, thereby introducing bias in favour of an ap-
parent harmful effect of antibiotics. Our comparison of different classes of antibiotics reduced
confounding due to the indication for antibiotic treatment (i.e. infection) whereby an apparent
association between prenatal antibiotics and adverse neurological outcome in childhood could
result from the underlying infection which is a cause for both the antibiotic treatment and the
brain damage manifesting as cerebral palsy and epilepsy. By examining only patients with an
antibiotic prescription (and thus a likely infection) we were able to minimise such indication
bias. This was particularly so for the comparison of macrolides versus penicillins as macrolides
are used as alternative treatment for the same indications in penicillin-allergic patients.[21]
Another limitation of the study is the measurement of antibiotic exposure. Firstly, we could
not capture antibiotics prescribed by maternity services. The prevalence of antibiotics pre-
scribed intrapartum and not recorded in primary-care is estimated to be less than 5% of preg-
nancies[28] but is not routinely documented in national data. Misclassification of women
treated by maternity services as untreated in primary-care would likely have had negligible ef-
fect due to small numbers among women delivering at or after term. Secondly, we could not
measure which women actually had their prescriptions dispensed and which women took anti-
biotics as prescribed. Few studies have quantified non-compliance in pregnancy, though this
may be as high as 39%.[39]
Our two-step approach to identifying children with cerebral palsy and epilepsy combined a
sensitive algorithm with manual review of full medical records to ensure we only classified
cases based on patterns of care in the longitudinal record that were consistent with cerebral
palsy or epilepsy. Our criteria were highly specific so it is possible that we missed some cases.
However, insensitive measurement of the outcome would not bias the relative effect.[40] Be-
cause antibiotics are frequently used in pregnancy, prescribing of antibiotics in primary-care is
unlikely to have an impact on ascertainment of cerebral palsy or epilepsy and also unlikely to
bias length of follow-up with the primary-care practice.
Using a composite outcome gave our analyses greater statistical power which enabled us to
explore the impact of timing, number of courses and type of antibiotic prescribed. Disadvan-
tages of using a composite outcome include the difficulty of determining specificity of adverse
effects—for cerebral palsy and/or epilepsy separately. Our post-hoc analyses suggest the find-
ings apply to epilepsy, but further studies are needed to explore a range of neurological
outcomes.
Mechanisms
Our study was not designed to replicate the OCS II which focused on women in spontaneous
preterm labour. However, it is intriguing that we found a similar association between maternal
macrolide prescribing and cerebral palsy or epilepsy in children born at term. We propose sev-
eral potential mechanisms for adverse effects of prenatal antibiotics—possibly arising from bi-
ases due to failure to account for ‘damaged-survivors’ and possibly through direct effects of
Prenatal Antibiotics, Cerebral Palsy and Epilepsy
PLOS ONE | DOI:10.1371/journal.pone.0122034 March 25, 2015 9/1 4macrolides. However, we would be cautious to draw a causal effect based on observational
data.
First, prenatal antibiotic treatment could shift the spectrum of fetal neurological-damage
caused by infection towards less severe outcomes—the ‘damaged-survivor’ hypothesis. This
mechanism could manifest by increased survival and less severe neurological manifestations in
survivors of treated versus untreated women. In OCS II, a shift may have affected a minority of
infected and neurologically-damaged fetuses, resulting in insufficient imbalance in numbers of
stillbirths, postnatal deaths or losses to follow-up (likely to be higher in more severely affected
survivors[41]), to reach statistical significance. A similar selection bias may have happened in
our cohort study and may have masked any benefits of prenatal antibiotics.
Second, partially treated infection may prolong exposure of the fetal brain to inflammation,
thereby increasing the risk of neuro-damage. This mechanism could be specific to macrolides
if women stopped taking erythromycin because of gastrointestinal side-effects,[42,43] or be-
cause of high rates of treatment failure from macrolide-resistant bacteria[44] or due to poor
transplacental passage of macrolide antibiotics (in comparison to ampicillin, [45,46] the most
commonly prescribed penicillin in pregnancy in UK primary-care[47]).
Third, macrolides may have a specific adverse effect on the fetus. There is a growing body of
evidence that macrolides are associated with adverse outcomes—including cardiovascular
events (including death) in adults [48–50], cardiotoxicity[51], and miscarriage[52]. Some stud-
ies have observed an association with macrolides and birth defects[53–55], whilst others have
not [56,57]. The exact mechanism for harm is unclear, though arrhythmia resulting from inhi-
bition of a cardiac potassium channel (IKr) and prolongation of the QT interval may play a
role.[58] In animal studies, drugs which block the IKr channel (e.g. macrolide antibiotics[51])
cause embryonic bradycardia, arrhythmia and cardiac arrest, even at concentrations that do
not affect the maternal heart.[59] The resulting temporary hypoxia (from interrupted-
/decreased oxygen supply) causes tissue damage.[60] Hypoxia in the first trimester is terato-
genic[61], resulting in an increased risk of transverse limb deficiencies and cardiac anomalies
with IKr-blocking drugs (e.g. macrolides[53,54], clomipramine and paroxetine[62], phenytoin
[61]). In addition to teratogenic effects, hypoxia is associated with failure of the fetus to grow
and thrive in the uterus,[63] which is associated with cerebral palsy.[64] Hypoxia, in associa-
tion with ischaemia and/or infection, is also thought to play a role in the aetiology of cerebral
palsy and epilepsy.[65–67]
Conclusions
We found no overall association between prescribing of any antibiotics during pregnancy and
cerebral palsy or epilepsy in childhood. However, we found that prenatal prescribing of macro-
lides versus penicillins was associated with an increase in the relative risk of cerebral palsy or
epilepsy in childhood, though the absolute risk remained low. This finding of harm associated
with macrolide use in pregnancy is consistent with findings from the OCS II trial and with
findings of adverse effects in other patient groups.
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